北海康成-B(01228)再涨超12%，截至发稿，涨11.98%，报1.87港元，成交额1844.94万港元。 同时，公司两家附属与百洋医药股份附属百洋附属订立一份战略合作及独家商业服务协议。据此，相关 附属同意委任百洋附属为独家合同销售组织，于内地、香港及澳门推广集团的若干产品。 消息面上，北海康成公布，向百洋医药（301015）(301015.SZ)发行7497万股新股，每股作价1.34港元， 较停牌前收报折让19.76%，认购事项所得款项净额约9866.18万港元，拟用于商业化产品的研发；营销 及推广活动；偿还贷款融资；及日常营运。完成后，百洋医药将持有公司股本14.99%，后者已表示其 无意于三年内收购公司任何控股股份。 ...

Core Viewpoint - Beihai Kangcheng-B (01228) has seen a significant increase in stock price, rising over 12% to HKD 1.87, with a trading volume of HKD 18.44 million [1] Group 1: Financial Actions - Beihai Kangcheng announced the issuance of 74.97 million new shares to Baiyang Pharmaceutical (301015.SZ) at a price of HKD 1.34 per share, representing a discount of 19.76% compared to the last trading price before suspension [1] - The net proceeds from the subscription amount to approximately HKD 98.66 million, which will be used for the development of commercialized products, marketing and promotional activities, loan repayment, and daily operations [1] Group 2: Strategic Partnerships - The company has entered into a strategic cooperation and exclusive commercial service agreement with subsidiaries of Baiyang Pharmaceutical, designating Baiyang's subsidiary as the exclusive sales organization for promoting several of the group's products in mainland China, Hong Kong, and Macau [1] - Following the share issuance, Baiyang Pharmaceutical will hold 14.99% of Beihai Kangcheng's equity, and it has stated that it does not intend to acquire any controlling stake in the company within the next three years [1]

Group 1 - North Sea Kangcheng-B signed a subscription agreement with Baiyang Health Industry International Trade Co., Ltd. to issue 74.9715 million shares at HKD 1.34 per share, representing a discount of approximately 19.76% compared to the previous trading day's closing price [2] - The subscription is expected to raise HKD 100 million, with net proceeds estimated at approximately HKD 98.6618 million, which will be used for product research and development, marketing promotion, loan repayment, and daily operations [2] - The company's shares will be suspended from trading starting at 9:00 AM on August 12, 2025, and will resume trading at 9:00 AM on August 13, 2025 [2]

格隆汇8月13日丨北海康成-B(01228.HK)发布公告，该公司的股份将于今天(13/8/2025)上午九时正起恢 复买卖。 ...

Core Viewpoint - Beihai Kangcheng-B (01228) has entered into a subscription agreement with Baiyang Health Industry International Trade Co., Ltd. to issue 74.9715 million shares at a subscription price of HKD 1.34 per share, representing a discount of approximately 19.76% from the closing price of HKD 1.67 on August 11, 2025 [1] Group 1 - The total amount raised from the subscription will be HKD 100 million, with a net amount of approximately HKD 98.6618 million after deducting related expenses [1] - The net proceeds from the subscription will be used for (i) research and development of commercialized products; (ii) marketing and promotional activities; (iii) repayment of loan financing and borrowings; and (iv) daily operations of the group [1] - Trading of the shares has been suspended on the Hong Kong Stock Exchange from 9:00 AM on August 12, 2025, at the company's request, with a resumption of trading expected on August 13, 2025 [1]

Core Viewpoint - The company, 北海康成-B (01228), has entered into a subscription agreement with 百洋健康产业国际商贸有限公司 to issue 74.9715 million shares at a subscription price of HKD 1.34 per share, representing a discount of approximately 19.76% from the closing price of HKD 1.67 on August 11, 2025 [1] Group 1 - The total amount raised from the subscription will be HKD 100 million, with a net amount estimated at approximately HKD 98.6618 million after deducting related expenses [1] - The net proceeds from the subscription are intended to be used for (i) research and development of commercialized products; (ii) marketing and promotional activities; (iii) repayment of loan financing and borrowings; and (iv) general operational activities of the group [1] - Trading of the company's shares was suspended on the Hong Kong Stock Exchange from 9:00 AM on August 12, 2025, at the request of the company, pending the announcement [1]

北海康成-B(01228)发布公告，于2025年8月11日，集团的两家附属公司与青岛百洋医药（301015）股份 有限公司(301015.SZ)(百洋医药)的一家附属公司(百洋附属公司)正式建立战略合作关系。 上述各方已订立一份战略合作及独家商业服务协议，据此，相关附属公司已同意委任百洋附属公司为独 家合同销售组织(CSO)，于中国内地、中国香港及中国澳门(相关地区)推广集团的若干产品，但须受集 团相关成员公司与该等产品各自的授权方所订立的上游授权协议(包括(在适用情况下)相关授权方的同 意)所规限。商业服务协议亦订明，百洋附属公司的联属公司可按百洋的选择担任该等产品于相关地区 的分销商。 ...

Core Viewpoint - North Sea Kangcheng-B (01228) has entered into a subscription agreement with Baiyang Health Industry International Trade Co., Ltd. to issue 74.9715 million subscription shares at a price of HKD 1.34 per share, representing a discount of approximately 19.76% from the closing price of HKD 1.67 on August 11, 2025 [1] Group 1 - The total amount raised from the subscription will be HKD 100 million, with a net amount estimated at approximately HKD 98.6618 million after deducting related expenses [1] - The net proceeds from the subscription will be used for (i) research and development of commercialized products; (ii) marketing and promotional activities; (iii) repayment of loan financing and borrowings; and (iv) daily operations of the group [1] - Trading of the shares has been suspended on the Hong Kong Stock Exchange from 9:00 AM on August 12, 2025, at the company's request, with a resumption of trading expected on August 13, 2025 [1]

Core Viewpoint - Beihai Kangcheng-B (01228) has announced a strategic partnership with a subsidiary of Qingdao Baiyang Pharmaceutical Co., Ltd. (301015.SZ) to promote certain products in mainland China, Hong Kong, and Macau through an exclusive commercial service agreement [1] Group 1 - The agreement establishes Baiyang's subsidiary as the exclusive Contract Sales Organization (CSO) for promoting the group's products in the specified regions [1] - The promotion is subject to the upstream authorization agreements established by the group's member companies and the respective product authorization [1] - Baiyang's affiliated companies may act as distributors for the products in the relevant regions at Baiyang's discretion [1]

上述各方已订立一份战略合作及独家商业服务协议，据此，相关附属公司已同意委任百洋附属公司为独 家合同销售组织(CSO)，于中国内地、香港及澳门推广集团的若干产品，惟须受集团相关成员公司与该 等产品各自的授权方所订立的上游授权协议(包括(在适用情况下)相关授权方的同意)所规限。商业服务 协议亦订明，百洋附属公司的联属公司可按百洋的选择担任该等产品于相关地区的分销商。 格隆汇8月12日丨北海康成-B(01228.HK)公告，于2025年8月11日，集团的两家附属公司与青岛百洋医药 股份有限公司(于深圳证券交易所上市的公司，股票代码：301015)("百洋医药")的一家附属公司("百洋附 属公司")正式建立战略合作关系。 ...